Publications in collaboration with researchers from Universitat Pompeu Fabra (18)

2024

  1. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

    Biomedicine and Pharmacotherapy, Vol. 176

  2. Validation of ZIP4 as a tumour-associated antigen for nanotargeting

    Journal of Drug Targeting

2020

  1. The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer

    Cells, Vol. 9, Núm. 3

2018

  1. Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing

    Nature, Vol. 560, Núm. 7719, pp. 441-446

2017

  1. A novel translational control mechanism involving RNA structures within coding sequences

    Genome Research, Vol. 27, Núm. 1, pp. 95-106

  2. Prognostic impact of CD133 expression in Endometrial Cancer Patients

    Scientific Reports, Vol. 7, Núm. 1

  3. Prognostic value of tumoral stem cells in glioblastoma: Immunohistochemical study of CD133 and HTERT expression

    Analytical and Quantitative Cytopathology and Histopathology, Vol. 39, Núm. 5, pp. 259-264

2016

  1. Snail1 is required for the maintenance of the pancreatic acinar phenotype

    Oncotarget, Vol. 7, Núm. 4, pp. 4468-4482

2014

  1. The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1

    Molecular and Cellular Biology, Vol. 34, Núm. 13, pp. 2479-2487

2012

  1. Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I2 receptor

    Journal of Medicinal Chemistry, Vol. 55, Núm. 22, pp. 9838-9846

  2. Key contribution of CPEB4mediated translational control to cancer progression

    Nature Medicine, Vol. 18, Núm. 1, pp. 83-90

2009

  1. FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, Núm. 7, pp. 1156-1166

  2. Galectin-1 Is a Novel Functional Receptor for Tissue Plasminogen Activator in Pancreatic Cancer

    Gastroenterology, Vol. 136, Núm. 4

2008

  1. Pancreatic ductal adenocarcinoma: Cellular origin, signaling pathways and stroma contribution

    Pancreatology, Vol. 8, Núm. 4-5, pp. 462-469

2007

  1. Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2

    American Journal of Pathology, Vol. 170, Núm. 5, pp. 1573-1584

2006

  1. A proteomic approach to the identification of new tPA receptors in pancreatic cancer cells.

    Proteomics, Vol. 6 Suppl 1

2004

  1. Tissue plasminogen activator in murine exocrine pancreas cancer: Selective expression in ductal tumors and contribution to cancer progression

    American Journal of Pathology, Vol. 165, Núm. 4, pp. 1129-1139

2003

  1. New insights into the tPA-annexin A2 interaction: Is annexin A2 Cys8 the sole requirement for this association?

    Journal of Biological Chemistry, Vol. 278, Núm. 8, pp. 5702-5709